Multiple murine BRaf(V600E) melanoma cell lines with sensitivity to PLX4032

The BRAF(V600E) mutation, which approaches 50% in human melanomas, constitutively activates pERK and contributes to disease progression. The BRAF(V600E) inhibitor, Vemurafenib (PLX4032), shows promising clinical responses, but resistance to PLX4032 usually develops within a year. Transgenic mouse mo...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Jenkins, Molly H., Steinberg, Shannon M., Alexander, Matthew P., Fisher, Jan L., Ernstoff, Marc S., Turk, Mary Jo, Mullins, David W., Brinckerhoff, Constance E.
Format: Artigo
Idioma:Inglês
Publicat: 2014
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3988244/
https://ncbi.nlm.nih.gov/pubmed/24460976
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/pcmr.12220
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars